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Context: The development and evolution of different chronic diabetic  complications may present variations among the different
types and conditions of this disease. Objective: To evaluate the degree of microangiopathy in Type 1 diabetes mellitus (DM1)
associated with autoimmune polyendocrinopathies (OSAD) or isolated DM1 (iDM1). Patients: OSAD (n=17) and iDM1 (n=13) were
over 15 years old at diagnosis of DM and were matched for diabetes duration (13.9 ± 8.2 and 13.2 ± 5.9 years, respectively) and
metabolic control (HbA1c: 6.4 ± 1.9 and 6.8 ± 1.4%). Main Outcome Measures: Urinary albumin excretion (UAE; ELISA), the
inversion of serum creatinine (1/C) level  and indirect ophthalmoscopy. Results: Although the prevalence of hypertension was
similar in both groups, the OSAD had inferior levels of UAE (7.4 ± 2.5 vs. 17.3 ± 9.2 µg/min; p< 0.05). Nephropathy was detected in
12% of the OSAD (none of them macroproteinuric) and in 39% of the iDM1 . The UAE in the iDM1 correlated negatively with 1/C
values (r= -0.7, p< 0.005), but the same did not occur in the OSAD  (r= 0.2, ns). Among patients with retinopathy, the severe form
was found in 29% of the OSAD and in 46% of the iDM1. Conclusions: OSAD was associated with a lower degree of microangiopathy,
in spite of age at diagnosis, duration of diabetes and the metabolic control. In contrast with the iDM1 , the increase in UAE of OSAD
was not associated with reductions in GFR.
Uniterms: Microangiopathy. Type 1 diabetes mellitus. Autoimmune poliendocrinopathies.
INTRODUCTION
he development and evolution of different chronic
diabetic complications may present variations
among the different types and conditions of this
disease. There may therefore exist different pathogenic
mechanisms for specific diabetes  complications. Several
factors, especially in type 1 diabetes, such as duration of
disease,1 time beyond puberty,2,3 arterial hypertension,4-7
metabolic control8,9 and a family history of hypertension10,11
can significantly modify the course of these complications.
In parallel, residual insulin secretion is related to better
metabolic control,12 which has a relationship with
development and progression of chronic diabetic
complications.8,9,13,14
An association between type 1 diabetes mellitus
(DM1) and other autoimmune diseases has been reported
several times in the last three decades.15-17 The associations
between the many organ-specific autoimmune diseases
(OSAD) have been classified as Polyglandular
Autoimmune Syndromes (PGAS), divided into two major
groups.18,19 In PGAS-I, DM1 occurs in children and is
uncommon, whereas in PGAS-II,  DM1 appears in almost
half the cases and it begins in the third or fourth decade of
life. When the onset of DM1 occurs at an adult age, as in
OSAD PGAS-II patients, this disease appears to have a
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better evolution, with slower loss of b-cell function and a
longer asymptomatic period before diabetes diagnosis than
the classical DM1.3,12,20,21
Microangiopathic diabetic complications have never
before been studied comparatively in these two groups of
DM1 patients. We do not yet know whether the persistence
of residual insulin secretion found in OSAD diabetic patients
or the associated polyendocrinopathies can modify the
course of complications in these patients. Thus, the aim of
this study was to investigate the degree of microangiopathy
in two groups of type 1 diabetes mellitus, associated with
PGAS-II or otherwise, and matched for metabolic control,
duration and age at diagnosis of diabetes mellitus.
METHODS
Thirty patients were randomly recruited from among
DM1 patients attending the Diabetes and Hypertension
Clinic of São Paulo Hospital, Federal University of São
Paulo, City of São Paulo, Brazil. We classified our DM1 in
accordance with the National Diabetes Data Group criteria.22
Seventeen DM1 patients presenting an association
with one or more organ-specific autoimmune diseases
(OSAD) and 13 patients showing isolated DM1, i.e.
without other endocrinopathy or family history of these
diseases (iDM1), were retrospectively studied.
All the patients studied had an onset of clinical diabetes
at or after 15 years of age and their diabetes lasted for more
than 5 years. The patients of both groups (iDM1 and OSAD)
were matched for diabetes duration and metabolic control.
The diagnosis of associated diseases was made (by
PTM, MBSF or SAD) via clinical and laboratorial reports
of specific glandular dysfunction and/or presence of
specific autoantibodies (anti-thyroidglobulin,anti-
thyroperoxidase). Patients with confirmed primary
endocrine deficiences were receiving appropriate
replacement hormone therapy, and those with active
Grave’s Disease were treated with antithyroid drugs.
Clinical Evaluation
The two groups of patients were compared for age,
age at diagnosis of diabetes, family history of diabetes or
other autoimmune diseases, diabetes duration, daily insulin
requirement (units of insulin per body weight unit per day),
presence of hypertension (if the patient was under any
treatment) and body mass index (kg/m²).
Arterial blood pressure (ABP) was measured in the
left arm, in a sitting position after a ten minute rest, using
a standard 12.5 cm cuff mercury sphygmomanometer
(Korotkoff phase I-V sounds).  Indirect optical fundoscopy
was performed by the same ophthalmologist (N.B.S.M.)
after mydriasis and angiofluorescence when necessary.
Retinopathy was classified according to the Diabetic
Retinopathy Research Group.23 The patients were divided
according to whether they had the incipient form of
retinopathy (background) or the severe form (pre-
proliferative or proliferative).
Laboratorial Evaluation
The patients were matched for the metabolic control
achieved by mean glycemia and glycosuria, obtained from
patients’ records from the last 5 years (from 3 months to
12 years). The last glucosilated hemoglobin (HbA1c)
obtained via affinity chromatography (normal value 3.5 -
5.3%)24 was also used for accessing metabolic control.
The grade of diabetic nephropathy was evaluated
(exercise, drugs and urinary infection excluded) by urinary
albumin excretion rate. This was analyzed in nocturnal
urinary samples by ELISA (normal value < 20 µg/min)25
and classified as microalbuminuria in the range 20-200
µg/min (incipient nephropathy) or macroalbuminuria if
>200 µg/min (overt/clinical nephropathy).26,27 The inverse
of serum creatinine (1/C) level was taken as an indirect
index of glomerular filtration rate (GFR).28
All patients were evaluate for thyroid autoantibodies:
TgAb (antithyroglobulin; ELISA)29 and TPO (thyroid
peroxidase antibodies; ELISA).30
Statistical Methods
The differences between groups were analyzed using
the unpaired Student’s t-test when normally distributed;
otherwise the Mann-Witney test was used. A finding was
considered significant if p< 0.05 on a two-tailed test.
Distribution of hypertension, retinopathy and overt and/
or incipient nephropathy were tested using Fisher’s exact
test. Correlations were tested with the Spearman rank-order
correlation. All results are given as mean (± SD) if normally
distributed, or otherwise as median ranges. The
albuminuria values were converted to logarithmic scale
to achieve a distribution near the normal curve, so the
geometric median was used (mean ± SD).
RESULTS
Organ-specific autoimmune diseases associated with
Type 1 diabetes in this group were: Hashimoto’s
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Thyroiditis (6/17, 35.3%); Grave’s Disease (5/17, 29.4%);
antithyroid autoantibodies alone - TgAb or TPO (3/17,
17.6%); precocious menopause (1/17, 5.9%); and vitiligo
(2/17, 11.8%).
The clinical and laboratorial characteristics are shown
in Table 1. As the groups were matched, they had the same
period of clinical diagnosis of DM: median 12 years, variation
from 5 to 35 years in OSAD vs. median 12 years with range
from 5 to 27 in iDM1 and metabolic control. The mean of
fasting glycemia in the last 6 years was 256 mg/dl (OSAD)
and 268 mg/dl (iDM1); HbA1c  was 6.4% (3.3 to 7.5 % -
OSAD) vs. 6.8% (3.2 to 8.8 - iDM1). The diabetic groups
had similar ages: 50 years old (28 to 71 - OSAD) vs. 37 years
old (29 to 61 - iDM1); and age at DM diagnosis: 32 years old
(16 to 53 - OSAD) vs. 26 years old (17 to 48 - iDM1). The
patients of the two groups also had similar insulin
requirements: 0.7 U/kg/day (0.4 to 1.0 U/kg/day - OSAD)
vs. 0.7 U/kg/day (0.5 to 1.8 U/kg/day - iDM1); and body
mass index: 23.5 kg/m2 (19.7 to 29.5 kg/m2 - OSAD) vs.
24.2 kg/m2 (18.8 to 26.5 kg/m2 - iDM1). Furthermore, neither
the systemic mean blood pressure (97.7 ± 8.4 - OSAD vs.
105.2 ± 16.7 mmHg -iDM1), nor the sistolic and diastolic
blood pressure were statistically different.
The prevalence of retinopathy was 82% (14/17) in
the OSAD group and 69% (9/13) in the iDM1 group (ns).
But, when we looked at the severity of this complication
in these two groups, we found that among OSAD patients
with retinopathy, only 36% had the severe form, in contrast
to 67% of the iDM1 patients with retinopathy, although
this was not statistically significant.
Only two (12%) of the 17 OSAD patients had
nephropathy, and both had  this in the incipient form. Five
of the 13 iDM1 patients (39%) had nephropathy, and 15%
had clinical nephropathy. The urinary albumin excretion
was lower in the OSAD group (7.4 ± 2.5 µg/min) than
among the iDM1patients (17.3 ± 9.2 µg/min; p< 0.05).
The glomerular filtration rate was not statistically different.
There was an inverse correlation between urinary albumin
excretion and glomerular filtration rate in the iDM1 group
(rs= -0.7, p< 0.05). However, this correlation was not
observed in the OSAD group (Figure 1). Moreover, the
prevalence of hypertension was similar: 53% in the OSAD
group and 61.5% in the iDM1 group (ns). There was a
significant association between nephropathy and
hypertension in the iDM1group (p= 0.04), but not in the
OSAD group (ns).
Table 1
Clinical and laboratorial characteristics of type 1 diabetes alone (iDM1) and associated with
polyendocrinopathies (OSAD).
Variable OSAD iDM1 significance
Number 17 13 p
AGE (yr) 50 (28 - 71) 37 (29 - 61) ns
TDDM (yr) 12 (5 - 35) 12 (5 - 27) ns
ADMD (yr) 32 (16 - 53) 26 (17 - 48) ns
IR (U/kg/day) 0.7 (0.4 - 1.0) 0.7 (0.5 - 1.8) ns
HYP (%) 53 % 61.5% ns
MBP (mmHg) 97.7±8.4 105.2±16.7 ns
SBP(mmHg) 128.8±11.7 135.5±21.1 ns
DBP (mmHg) 81.8±9.3 89.8±15.1 ns
BMI (kg/m2) 23.5 (19.7 - 29.5) 24.2 (18.8 - 26.5) ns
FGLY (mg/dl) 256 (125-311) 268 (143-296) ns
HBA1c (%) 6.4 (3.3 - 7.5) 6.8 (3.2 - 8.8) ns
DR I/S(n) 9/5 3/6 ns
UAE (mg/min) 7.4x/¸2.5 17.3x/¸9.2 < 0.05
C (mg/dl) 0.7±0.2 1.0±0.6 ns
Values as Mean±SD or Median (variation). UAE in geometric average x/¸SD
TDDM: Time of Diagnosis of Diabetes Mellitus; ADMD: Age at Diabetes Mellitus Diagnosis; IR: Insulin Requirement; HYP: prevalence of
Sistemic Arterial Hypertension; MBP: Mean Blood Pressure; BMI: Body Mass Index; FGLY (mean of fasting glycemia in the last 5 years);
HbA1c: glycosilated haemoglobin; DR I/S (Diabetic Retinopathy Incipient/Severe); UAE: Urinary Albumin Excretion Rate; C: serum
creatinine
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DISCUSSION
This study demonstrates the differences in severity
of diabetic complications, under the same conditions,
between isolated type 1 diabetes and that associated with
other autoimmune endocrinopathies, for the first time to
our knowledge. The two groups were matched for diabetes
duration and metabolic control over the last 6 years. They
also had the same daily insulin requirement, which may
imply a similar residual insulin secretion.12,13
In an old study by Bottazzo et al,31 when looking for
an association between thyrogastric autoantibodies and
islet-cell autoantibodies among the families of juvenile
diabetes sufferers, they observed that the families with
evidence of organ-specific autoimmunity appeared to have
a higher frequency of vascular complications. However,
the patients were not matched for diabetes duration (the
OSAD patients had diabetes for a longer time), nor for
diabetes glycemic control. Also, only the macroproteinuric
nephropathy phase was evaluated. Another study analyzed
the prevalence of retinopathy in the presence of coincident
autoimmune disease to a degree sufficient for producing
thyroid failure or thyrotoxicosis, and found that it neither
protects against nor contributes to retinopathy.32 These
patients were not matched for diabetes control.
Microvascular complications develop in many
patients with DM1, but their prevalence and severity are
influenced by various genetic10,11 and metabolic8,9 factors,
and there may be other, as yet unknown factors. Regarding
retinopathy, although the background form is virtually
universal after 20 years of diabetes duration, the
proliferative forms affect 70% of DM1 subjects after 30
years of the disease.4,7 On the other hand, nephropathy,
the strongest predictor of premature death and
cardiovascular diseases in diabetic patients, occurs in only
40% of diabetic patients, even in cases of long diabetes
duration.6
In general, the progression and intensity of
retinopathy are related to poor metabolic control,14,28,33
Figure 1 - Correlation between urinary albumin excretion (UAE, expressed as logarithm) and the inverse of serum creatinine values
(1/C, as an indirect index of glomerular filtration rate) in the OSAD and iDM1 groups.
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smoking,7 systemic pressure levels 4.34 (especially
diastolic blood pressure)35 and genetically determined
immunopathic mechanisms.36 The degree of metabolic
control achieved in both groups studied was the same, and
it can be considered good because glycosylated
hemoglobin levels remained no more than 1.5% above the
upper limit for normality (6.2 and 6.8 vs. 5.3%). There
were no differences related to prevalence of hypertension
and pressure control between the two groups studied,
although hypertensive patients were treated. In the OSAD
group a greater but not statistically different prevalence
of all retinopathy was observed. However, in the iDM1
group with the same diabetes duration and metabolic
control, a tendency to greater severity in retinopathy was
observed. We should also take into account that the true
diabetes duration could be underestimated in the OSAD
group due to its sometimes more insidious onset.37
Comparing our data with the epidemiological study
of Parving et al,38 which analyzed DM1 patients of
comparable age (42 years old) and slightly longer diabetes
duration (21 years) than our groups, we can see almost
the same prevalence of hypertension (41% vs. 61.5% in
our iDM1 and 53% in OSAD) and total retinopathy (78%
vs. 69% in our iDM1 and 82% in OSAD). However, the
prevalence of proliferative retinopathy in our iDM1
patients was much higher (47% vs. 23% in OSAD and
36% in Parving’s study). Another study showed that the
incidence of proliferative retinopathy was 33% in a 40-
year follow-up.39 It is worth remembering that the
prevalence of hypertension in the two groups studied was
almost the same. Another point is that in other studies there
may also be OSAD patients, with diabetic control and
adherence to treatment, but with different genetic and
social situations.
The prevalence of nephropathy in our iDM1 patients
was almost the same as found in Parving’s study (39% vs.
41%, respectively),38 as was the prevalence of microal-
buminuria (23% vs. 22%, respectively). However, clinical
nephropathy (macroalbuminuria) was found in 12% of our
iDM1 patients and in 19% in the Scandinavian study
against none (0%) of the OSAD patients studied.
The prevalence of clinical nephropathy in other
studies was much higher (35 to 42%).40,41 In the classical
evolution of nephropathy in type 1 diabetes, the main
associated factor is the presence of hypertension,7,10,35,42,43
as well as the metabolic control.1,9,34 However, hypertension
was associated with nephropathy in the iDM1 group, as
expected, but not in the OSAD group. Another fact was
that albuminuria, which is a classical marker of
nephropathy,26,27,44 was higher and it was not correlated
with glomerular filtration rate in OSAD patients in spite
of the inverse correlation in the iDM1 group.
The correlation between albuminuria and glomerular
filtration rate is controversial, with different behaviour in
patients with type 1 diabetes. Some studies have found a a
strong correlation, whereas others have not.45 The
variability in albuminuria measurements and the
hyperfiltration shown by these patients could explain these
differences.45 Even so, the presence of hypertension and/
or abnormal levels of urinary albumin excretion does not
seem have the same prognostic value in type 1 diabetes,
whether associated with PGAS or not,  and OSAD  patients
could contribute to the confusion in the establishment of a
relationship between EUA and GFR.
The genes related to PGAS-II may be in linkage
disequilibrium with other genes that raise the microvascular
risks.18,46-48 Therefore genetic factors should be associated
with this particular course of diabetic complications in the
OSAD group. Furthermore, the pancreas immunological
destruction process rate in OSAD and iDM1 is also different.
The OSAD patients remain with high levels of anti-islet
cell antibodies for a long time, sometimes for more than 10
years without clinical diabetes, different to what can occur
in iDM1 patients.49-54 This study suggests that chronic
microangiopathic complications in type 1 diabetes
associated with polyendocrinopathies may have different
behavior in relation to isolated type 1 DM. It has apparently
less severe evolution of diabetic microvascular
complications than type 1 diabetes alone, in spite of the
diabetes duration, age at onset of diabetes and metabolic
control. Albuminuria and hypertension in these patients are
probably not associated with the level of renal impairment.
More studies on this particular group of patients should be
done in order to evaluate new, previously unrecognized
genetic, immunological or endocrinological  influences on
the course of diabetic microangiopathies.
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RESUMO
Contexto: O desenvolvimento  e evolução das complicações crônicas do diabetes mellitus podem apresentar diiferenças
entre os vários tipos e condições desta doença. Objetivo: Avaliar o grau de microangiopatia em pacientes com diabetes
mellitus do Tipo 1 (DM1)  associado ( OSAD)  ou não (DM1i) a endocrinopatias auto-imunes. Pacientes: Os OSAD (n= 17) e
os DM1i (n= 13) eram pareados para o tempo de duração do diabetes (13.9 ± 8.2 e 13.2 ± 5.9 anos, respectivamente) e
controle metabólico (HbA1c: 6.4 ± 1.9 e 6.8 ± 1.4%). Variáveis Estudadas: A  excreção urinária de albumina (EUA), o inverso
da creatinina sérica (1/C) e o grau de retinopatia diabética (oftalmoscopia indireta). Resultados: A  prevalência de hipertensão
arterial foi semelhante nos grupos e os OSAD tinham níveis inferiores de EUA (7.4 ± 2.5 vs. 17.3 ± 9.2 µg/min; p< 0.05). A
nefropatia diabética foi detectada em 12% dos OSAD (nenhum deles com macroproteinúria) e em 39% dos DM1i. Nos DM1i
havia uma correlação inversa entre a EUA e o 1/C (r= -0,7, p< 0,005), o mesmo não ocorria no OSAD (r= 0,2, ns). Retinopatia
em grau severo: 29% do  OSAD e 46% do DM1i. Conclusões: O presente estudo sugere que os OSAD apresentam uma
evolução melhor das microangiopatias quando comparado ao  DM1i nas mesmas condições. Nos DM1i o aumento da EUA
estava inversamente associada ao RFG e o mesmo não ocorria nos OSAD.
Monteagudo PT, Freire MBS, Moraes NSB, Dib SA. Microangiopathic complications in type
1 diabetes mellitus: Differences in severity when isolated or associated with autoimmune
polyendocrinopathies.
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